Epigenetic therapies in solid tumours: From preclinical models to clinical trial results

Epigenetic Therapy of Cancer: Preclinical Models and Treatment Approaches

Volumn 9783642384042, Issue , 2014, Pages 299-317

  Brown, Robert ^a   Steinmann, Juliane ^c   Graham, Janet ^a   Glasspool, Ros ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84922502301     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-38404-2_13     Document Type: Chapter

References (114)

1. Abele R, Clavel M, Dodion P et al (1987) The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol 23:1921-1924
2. Aparicio A, Eads CA, Leong LA et al (2003) Phase I trial of continuous infusion 5-aza-2-deoxycytidine. Cancer Chemother Pharmacol 51:231-239
3. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schatzlein A, Twelves C, Kaye SB, Brown R (2007) Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25:4603-4609
4. Atmaca A, Al-Batran SE, Maurer A et al (2007) Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 97:177-182
5. Bandyopadhyay D, Mishra A, Medrano EE (2004) Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res 64:7706-7710
6. Bauman J, Verschraegen C, Belinsky S et al (2012) A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies. Cancer Chemother Pharmacol 69:547-554
7. Bi G, Jiang G (2006) The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol 3:285-290
8. Bitzer M (2012) 4SC-201 (resminostat) and sorafenib in advanced hepatocellular carcinoma (Shelter). ClinicalTrials.gov: http://clinicaltrials.gov/ct2/show/NCT00943449term=resminost at+hcc=1
9. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR (2008) Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 26:81-87
10. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784
11. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK, Melton DA, Jaenisch R, Young RA (2005) Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122:947-956
12. Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, Pili R, Zwiebel J, Scher H, Hussain M (2009) Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 115:5541-5549
13. Brueckner B, Kuck D, Lyko F (2007) DNA methyltransferase inhibitors for cancer therapy. Cancer J 13:17-22
14. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT (2007) EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 67:547-556
15. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107
16. Candelaria M, Gallardo-Rincón D, Arce C et al (2007) A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 18:1529-1538
17. Cao R, Zhang Y (2004) The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 14:155-164
18. Chapman-Rothe N, Brown R (2009) Approaches to target the genome and its epigenome in cancer. Future Med Chem 1:1481-1495
19. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA, Selker EU (2003) Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95:399-409
20. Chinnaiyan P, Chowdhary S, Potthast L et al (2012) Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Neuro Oncol 14:93-100
21. Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA (2006) Expression of enhancer of zeste homologue 2 is signifi cantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 12:1168-1174
22. Creagan ET, Schaid DJ, Hartmann LC et al (1993) A phase II study of 5, 6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma. Am J Clin Oncol 16:243-244
23. Dasari A, Gore L, Messersmith WA et al (2012) A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and nonsmall cell lung cancer. Invest New Drugs. doi: 10.1007/s10637-012-9812-z
24. Daud AI, Dawson J, DeConti RC et al (2009) Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res 15:2479-2487
25. Dizon DS, Blessing JA, Penson RT et al (2012a) A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 125:367-371
26. Dizon DS, Damstrup L, Finkler NJ et al (2012b) Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. Int J Gynecol Cancer 22:979-986
27. Doi T, Hamaguchi T, Shirao K et al (2012) Evaluation of safety, pharmacokinetics, and effi cacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. Int J Clin Oncol. doi: 10.1007/s10147-011-0348-6
28. Drappatz J, Lee EQ, Hammond S et al (2012) Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol 107:133-138
29. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31-39
30. Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, Boileau K, Gunchenko A, Sanz-Rodriguez C, Geskin LJ (2009) Evaluation of the long-term tolerability and clinical benefi t of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 9:412-416
31. Egerer G (2012) Study on effi cacy and tolerability of vorinostat in patients with advanced, metastatic soft tissue sarcoma (STS) (SAHA-I). ClinicalTrials.gov: http://www.clinicaltrials.gov/ct2/show/NCT00918489term=sarcoma+vorinostat=1
32. Fakih MG, Groman A, McMahon J et al (2012) A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. Cancer Chemother Pharmacol 69:743-751
33. Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP, Matei DE (2010) A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 116:4043-4053
34. Friday BB, Anderson SK, Buckner J et al (2012) Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol 14:215-221
35. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC Jr (2011) Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117:1661-1669
36. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J, Buckner JC (2009) Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27:2052-2058
37. George RE, Lahti JM, Adamson PC, Zhu K, Finkelstein D, Ingle AM, Reid JM, Krailo M, Neuberg D, Blaney SM, Diller L (2010) Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 55:629-638
38. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R (2004) The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10:4420-4426
39. Glasspool RM, Teodoridis JM, Brown R (2006) Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 94:1087-1092
40. Glasspool RM, Gore M, Rustin G, Mcneish I, Wilson R, Pledge S (2009) Randomized phase Ii study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer. J Clin Oncol 27:15S
41. Gollob JA, Sciambi CJ, Peterson BL et al (2006) Phase I trial of sequential low-dose 5-aza-2-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 12:4619-4627
42. Graham JS, Kaye SB, Brown R (2009) The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer 45:1129-1136
43. Haigentz M Jr, Kim M, Sarta C et al (2012) Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol 48:1281-1288
44. Hainsworth JD, Infante JR, Spigel DR et al (2011) A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest 29:451-455
45. Hauschild A, Trefzer U, Garbe C et al (2008) Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res 18:274-278
46. Holleran JL, Parise RA, Joseph E, Eiseman JL, Covey JM, Glaze ER, Lyubimov AV, Chen YF, D'Argenio DZ, Egorin MJ (2005) Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 11:3862-3868
47. Holoye PY, Dhingra HM, Umsawasdi T et al (1987) Phase II study of 5, 6-dihydro-5-azacytidine in extensive, untreated non-small cell lung cancer. Cancer Treat Rep 71:859-860
48. Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, Xiao L, Wang Z (2010) Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther(10)
49. Issa JP, Kantarjian HM (2009) Targeting DNA methylation. Clin Cancer Res 15:3938-3946
50. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635-1640
51. Iwamoto FM, Lamborn KR, Kuhn JG et al (2011) A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol 13:509-516
52. Jones PA (1985) Altering gene expression with 5-azacytidine. Cell 40:485-486
53. Juergens RA, Wrangle J, Vendetti FP et al (2011) Combination epigenetic therapy has effi cacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 1:598-607
54. Kantarjian HM, Issa JP (2005) Decitabine dosing schedules. Semin Hematol 42:S17-S22
55. Karanikolas BD, Figueiredo ML, Wu L (2009) Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol Cancer Res 7:1456-1465
56. Kelly WK, O'Connor OA, Krug LM et al (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931
57. Khan O, Fotheringham S, Wood V, Stimson L, Zhang C, Pezzella F, Duvic M, Kerr DJ, La Thangue NB (2010) HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci USA 107:6532-6537
58. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291-7300
59. Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G (2008) A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res 14:2444-2449
60. Kristensen LS, Nielsen HM, Hansen LL (2009) Epigenetics and cancer treatment. Eur J Pharmacol 625:131-142
61. Lee J, McGuire C (2012) Clinical effi cacy of vorinostat in a patient with leiomyosarcoma. Clin Med Insights Oncol 6:101-105
62. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B, Johnstone SE, Cole MF, Isono K, Koseki H, Fuchikami T, Abe K, Murray HL, Zucker JP, Yuan B, Bell GW, Herbolsheimer E, Hannett NM, Sun K, Odom DT, Otte AP, Volkert TL, Bartel DP, Melton DA, Gifford DK, Jaenisch R, Young RA (2006) Control of developmental regulators by polycomb in human embryonic stem cells. Cell 125:301-313
63. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio A, Gandara DR, Somlo G (2008) A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 14:7138-7142
64. Lyko F, Brown R (2005) DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 97:1498-1506
65. Mackay HJ, Hirte H, Colgan T et al (2010) Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer 46:1573-1579
66. Martin V, Jorgensen HF, Chaubert AS, Berger J, Barr H, Shaw P, Bird A, Chaubert P (2008) MBD2-mediated transcriptional repression of the p14ARF tumor suppressor gene in human colon cancer cells. Pathobiology 75:281-287
67. Matei D, Fang F, Shen C et al (2012) Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 72:2197-2205
68. Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H (2006) Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 97:484-491
69. Millward M, Price T, Townsend A et al (2012) Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs 30:2303-2317
70. Modesitt SC, Sill M, Hoffman JS, Bender DP (2008) A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 109:182-186
71. Momparler RL, Ayoub J (2001) Potential of 5-aza-2-deoxycytidine (decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 34(Suppl 4):S111-S115
72. Momparler RL, Bouchard J, Onetto N, Rivard GE (1984) 5-aza-2-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. Leuk Res 8:181-185
73. Momparler RL, Bouffard DY, Momparler LF et al (1997) Pilot phase I-II study on 5-aza-2-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8:358-368
74. Mund C, Lyko F (2010) Epigenetic cancer therapy: proof of concept and remaining challenges. Bioessays 32:949-957
75. Munster PN, Marchion D, Thomas S et al (2009a) Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 101:1044-1050
76. Munster P, Marchion D, Bicaku E et al (2009b) Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 15:2488-2496
77. Munster PN, Thurn KT, Thomas S et al (2011) A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapyresistant breast cancer. Br J Cancer 104:1828-1835
78. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER, van der Heijden A, Scheele TN, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH (2010) Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42:665-667
79. Oki Y, Aoki E, Issa JP (2007) Decitabine-bedside to bench. Crit Rev Oncol Hematol 61:140-152
80. Otterson GA, Hodgson L, Pang H et al (2010) Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol 5:1644-1648
81. Pediconi N, Ianari A, Costanzo A, Belloni L, Gallo R, Cimino L, Porcellini A, Screpanti I, Balsano C, Alesse E, Gulino A, Levrero M (2003) Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol 5:552-558
82. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R (2000) Reversal of drug resistance in human tumor xenografts by 2-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60:6039-6044
83. Plummer R, Vidal L, Griffi n M, Lesley M, de Bono J, Coulthard S, Sludden J, Siu LL, Chen EX, Oza AM, Reid GK, McLeod AR, Besterman JM, Lee C, Judson I, Calvert H, Boddy AV (2009) Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin Cancer Res 15:3177-3183
84. Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, Jeffers M (2006) Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 5:2086-2095
85. Quinn D (2012) Vorinostat in treating patients with locally recurrent or metastatic cancer of the urothelium. ClinicalTrials.gov: http://clinicaltrials.gov/ct2/show/NCT00363883term=Bladde r+cancer+vorinostat=1
86. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara DR, Belani CP (2010) Carboplatin and paclitaxel in combination with either vorinostat or placebo for fi rst-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 28:56-62
87. Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF, Liao YJ, Deng HX, Chen YC, Guan XY, Zeng YX, Kung HF, Xie D (2010) EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-{beta}1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 31:1576-1583
88. Rathkopf D, Wong BY, Ross RW et al (2010) A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 66:181-189
89. Reid GK, Besterman JM, MacLeod AR (2002) Selective inhibition of DNA methyltransferase enzymes as a novel strategy for cancer treatment. Curr Opin Mol Ther 4:130-137
90. Rizzo S, Hersey J, Graham J, Zeller C, Huang TH, Yan P, Vass JK, Brown R, Paul J (2011) Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 10:325-335
91. Sansom OJ, Maddison K, Clarke AR (2007) Mechanisms of disease: methyl-binding domain proteins as potential therapeutic targets in cancer. Nat Clin Pract Oncol 4:305-315
92. Sauvageau M, Sauvageau G (2008) Polycomb group genes: keeping stem cell activity in balance. PLoS Biol 6:e113
93. Schrump DS, Fischette MR, Nguyen DM et al (2006) Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 12:5777-5785
94. Schwartsmann G, Schunemann H, Gorini CN, Filho AF, Garbino C, Sabini G, Muse I, DiLeone L, Mans DR (2000) A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 18:83-91
95. Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, Garcia-Vargas J, Sanz-Rodriguez C, Rizvi S (2009) Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2:31
96. Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647:21-29
97. Stathis A, Hotte SJ, Chen EX et al (2011) Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res 17:1582-1590
98. Steele NL, Plumb JA, Vidal L, Tjornelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TR, DeBono JS (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14:804-810
99. Steele N, Finn P, Brown R, Plumb JA (2009) Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 100:758-763
100. Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, Marquez VE, Clement V, Stamenkovic I (2009) EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 69:9211-9218
101. Takai N, Narahara H (2010) Histone deacetylase inhibitor therapy in epithelial ovarian cancer. J Oncol 2010:458431
102. Teodoridis JM, Strathdee G, Plumb JA, Brown R (2004) CpG-island methylation and epigenetic control of resistance to chemotherapy. Biochem Soc Trans 32:916-917
103. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R (2005) CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65:8961-8967
104. Thibault A, Figg WD, Bergan RC et al (1998) A phase II study of 5-aza-2-deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 84:87-89
105. Traynor AM, Dubey S, Eickhoff JC et al (2009) Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol 4:522-526
106. Winquist E, Knox J, Ayoub JP, Wood L, Wainman N, Reid GK, Pearce L, Shah A, Eisenhauer E (2006) Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs 24:159-167
107. Witt O, Schweigerer L, Driever PH et al (2004) Valproic acid treatment of glioblastoma multiforme in a child. Pediatr Blood Cancer 43:181
108. Witta SE, Jotte RM, Konduri K et al (2012) Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol 30:2248-2255
109. Wong NS, Seah EZ, Wang LZ et al (2011) Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer. Pharmacogenet Genomics 21:760-768
110. Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26:5541-5552
111. Yang YT, Balch C, Kulp SK, Mand MR, Nephew KP, Chen CS (2009) A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia 11:552-563.
112. Yogelzang NJ, Herndon JE 2nd, Cirrincione C et al (1997) Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer 79:2237-2242
113. Yoo CB, Jeong S, Egger G, Liang G, Phiasivongsa P, Tang C, Redkar S, Jones PA (2007) Delivery of 5-aza-2-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 67:6400-6408
114. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP (2002) Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 321:591-599